CR10102A - Acido 3-(4-{[4-(4{[3-(3,3,-dimetil-1piperidinil) propil) oxi} fenil)1-piperidinil]carbonil}-1-naftalenil)propanoico o proponeico como antagonistas del receptor h1 h3 para el tratamiento de disfunciones inflamatorias y/o alergicas - Google Patents

Acido 3-(4-{[4-(4{[3-(3,3,-dimetil-1piperidinil) propil) oxi} fenil)1-piperidinil]carbonil}-1-naftalenil)propanoico o proponeico como antagonistas del receptor h1 h3 para el tratamiento de disfunciones inflamatorias y/o alergicas

Info

Publication number
CR10102A
CR10102A CR10102A CR10102A CR10102A CR 10102 A CR10102 A CR 10102A CR 10102 A CR10102 A CR 10102A CR 10102 A CR10102 A CR 10102A CR 10102 A CR10102 A CR 10102A
Authority
CR
Costa Rica
Prior art keywords
treatment
proponeic
naftalenil
piperidinil
dimetil
Prior art date
Application number
CR10102A
Other languages
English (en)
Inventor
Teanby Hodgson Simon
Alexandrou Procopiou Panayiotis
Victoria Vinader Brugarolas Maria
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0525897A external-priority patent/GB0525897D0/en
Priority claimed from GB0623217A external-priority patent/GB0623217D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CR10102A publication Critical patent/CR10102A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a un compuesto de la fórmula (I), o una sal del mismo en donde el anillo de naftaleno puede ser sustituido en la s posiciones 2, 3, 4, 5, 6, 7 o 8 por R1, y R1 representa -CH2CH2COOH o -CH=C (CH3) COOH, y a procesos para su preparación, a composiciones que los contienen y su uso en el tratamiento de varias enfermedades de rinitis alérgica.
CR10102A 2005-12-20 2008-06-20 Acido 3-(4-{[4-(4{[3-(3,3,-dimetil-1piperidinil) propil) oxi} fenil)1-piperidinil]carbonil}-1-naftalenil)propanoico o proponeico como antagonistas del receptor h1 h3 para el tratamiento de disfunciones inflamatorias y/o alergicas CR10102A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0525897A GB0525897D0 (en) 2005-12-20 2005-12-20 Compounds
GB0623217A GB0623217D0 (en) 2006-11-21 2006-11-21 Compounds

Publications (1)

Publication Number Publication Date
CR10102A true CR10102A (es) 2008-09-22

Family

ID=37845266

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10102A CR10102A (es) 2005-12-20 2008-06-20 Acido 3-(4-{[4-(4{[3-(3,3,-dimetil-1piperidinil) propil) oxi} fenil)1-piperidinil]carbonil}-1-naftalenil)propanoico o proponeico como antagonistas del receptor h1 h3 para el tratamiento de disfunciones inflamatorias y/o alergicas

Country Status (24)

Country Link
US (1) US7989629B2 (es)
EP (2) EP1963307B1 (es)
JP (2) JP4445570B2 (es)
KR (1) KR20080087102A (es)
AR (1) AR058109A1 (es)
AT (1) ATE449769T1 (es)
AU (1) AU2006328512B2 (es)
BR (1) BRPI0620218A2 (es)
CA (1) CA2634391A1 (es)
CR (1) CR10102A (es)
CY (1) CY1110601T1 (es)
DE (1) DE602006010737D1 (es)
DK (1) DK1963307T3 (es)
EA (1) EA014354B1 (es)
ES (1) ES2337187T3 (es)
IL (1) IL191967A0 (es)
MA (1) MA30373B1 (es)
NO (1) NO20082695L (es)
PE (1) PE20071068A1 (es)
PL (1) PL1963307T3 (es)
PT (1) PT1963307E (es)
SI (1) SI1963307T1 (es)
TW (1) TW200730498A (es)
WO (1) WO2007071691A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5791500B2 (ja) 2008-05-23 2015-10-07 パンミラ ファーマシューティカルズ，エルエルシー． ５−リポキシゲナーゼ活性化タンパク質阻害剤
US20120149731A1 (en) 2009-06-29 2012-06-14 Glaxo Group Limited New medical use
JP4785963B2 (ja) 2009-10-09 2011-10-05 キヤノン株式会社 固体撮像装置
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
WO2015173701A2 (en) 2014-05-12 2015-11-19 Glaxosmithkline Intellectual Property (No. 2) Limited Pharmaceutical compositions for treating infectious diseases
KR101640756B1 (ko) 2014-10-28 2016-07-19 이종찬 전동 드릴 장착용 내시경 캡
WO2019169082A1 (en) * 2018-03-01 2019-09-06 Ferox Therapeutics Llc Methods of preventing and treating hypoglycemia in type 1 and type 2 diabetes patients
CA3173172A1 (en) 2020-03-26 2021-09-30 Christopher D. Kane Cathepsin inhibitors for preventing or treating viral infections

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9127376D0 (en) 1991-12-24 1992-02-19 Wellcome Found Amidino derivatives
FI944549L (fi) 1992-04-02 1994-11-30 Smithkline Beecham Corp Allergisten ja tulehdussairauksien hoidossa käyttökelpoiset yhdisteet
JPH07509694A (ja) 1992-05-14 1995-10-26 ベイラー・カレッジ・オブ・メディシン 突然変異したステロイドホルモン受容体，その使用方法および遺伝子治療のための分子スイッチ
US5364791A (en) 1992-05-14 1994-11-15 Elisabetta Vegeto Progesterone receptor having C. terminal hormone binding domain truncations
EP0957087B1 (en) 1994-06-15 2002-12-04 The Wellcome Foundation Limited Intermediates useful in the preparation of enzyme inhibitors
MY117948A (en) 1997-01-13 2004-08-30 Glaxo Group Ltd Nitride oxide synthase inhibitors.
DE19723722A1 (de) 1997-05-30 1998-12-10 Schering Ag Nichtsteroidale Gestagene
WO1999016766A1 (en) 1997-10-01 1999-04-08 Kyowa Hakko Kogyo Co., Ltd. Benzodioxole derivatives
US6506766B1 (en) 1998-02-13 2003-01-14 Abbott Laboratories Glucocortiocoid-selective antinflammatory agents
SI1070056T1 (en) 1998-03-14 2004-12-31 Altana Pharma Ag Phthalazinone pde iii/iv inhibitors
GB9811599D0 (en) 1998-05-30 1998-07-29 Glaxo Group Ltd Nitric oxide synthase inhibitors
AU4501800A (en) 1999-05-04 2000-11-17 American Home Products Corporation Tetracyclic progesterone receptor modulator compounds and methods
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
CO5180649A1 (es) 1999-09-01 2002-07-30 Abbott Lab Antagonistas de los receptores de los glucocorticoides para el tratamiento de la diabetes para el tratamiento de la diabetes
OA11558A (en) 1999-12-08 2004-06-03 Advanced Medicine Inc Beta 2-adrenergic receptor agonists.
CA2417826A1 (en) 2000-08-05 2002-02-14 Glaxo Group Limited 17.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derivative as anti-inflammatory agents
GB0031179D0 (en) 2000-12-21 2001-01-31 Glaxo Group Ltd Nitric oxide synthase inhibitors
US6484903B2 (en) 2001-01-09 2002-11-26 Riverwood International Corporation Carton with an improved dispensing feature in combination with a unique handle
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
JP2004526720A (ja) 2001-03-08 2004-09-02 グラクソ　グループ　リミテッド βアドレナリン受容体のアゴニスト
ATE381537T1 (de) 2001-03-22 2008-01-15 Glaxo Group Ltd Formanilid-derivative als beta2-adrenorezeptor- agonisten
ES2438985T3 (es) 2001-09-14 2014-01-21 Glaxo Group Limited Formulación de inhalación que comprende derivados de fenetanolamina para el tratamiento de enfermedades respiratorias
US6653323B2 (en) 2001-11-13 2003-11-25 Theravance, Inc. Aryl aniline β2 adrenergic receptor agonists
EP1467982B8 (en) 2002-01-14 2007-04-11 Boehringer Ingelheim Pharmaceuticals Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical formulations containing them, and uses thereof
CA2473886C (en) 2002-01-22 2012-08-21 The Regents Of The University Of California Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof
GB0204719D0 (en) 2002-02-28 2002-04-17 Glaxo Group Ltd Medicinal compounds
JP4324480B2 (ja) 2002-03-26 2009-09-02 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド グルココルチコイドミメティクス、その製法、医薬組成物、及び使用
EP1490317A1 (en) 2002-03-26 2004-12-29 Boehringer Ingelheim Pharmaceuticals Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
DE10215316C1 (de) 2002-04-02 2003-12-18 Schering Ag Chinolin- und Isochinolin-Derivate, ein pharmazeutisches Mittel und ihre Verwendung als Entzündungshemmer
WO2003086294A2 (en) 2002-04-11 2003-10-23 Merck & Co., Inc. 1h-benzo[f]indazol-5-yl derivatives as selective glucocorticoid receptor modulators
ATE381535T1 (de) 2002-04-25 2008-01-15 Glaxo Group Ltd Phenethanolaminderivate
US7186864B2 (en) 2002-05-29 2007-03-06 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US7074806B2 (en) 2002-06-06 2006-07-11 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
WO2004005229A1 (en) 2002-07-08 2004-01-15 Pfizer Products Inc. Modulators of the glucocorticoid receptor
JP2006508042A (ja) 2002-07-18 2006-03-09 ブリストル−マイヤーズ　スクイブ　カンパニー グルココルチコイド受容体の修飾物質および方法
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
CA2496175A1 (en) 2002-08-21 2004-03-04 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted hihydroquinolines as glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
GB0220730D0 (en) 2002-09-06 2002-10-16 Glaxo Group Ltd Medicinal compounds
GB0230045D0 (en) 2002-12-23 2003-01-29 Glaxo Group Ltd Compounds
BR0314392A (pt) 2002-09-16 2005-07-12 Glaxo Group Ltd Composto ou um sal do mesmo, composição farmacêutica, uso de um composto, método de tratamento e/ou profilaxia de uma doença inflamatória e/ou alérgica ou deficiência cognitiva em um mamìfero, e, combinação
AU2003270783C1 (en) 2002-09-20 2010-05-20 Merck Sharp & Dohme Corp. Octahydro-2-H-naphtho[1,2-F] indole-4-carboxamide derivatives as selective glucocorticoid receptor modulators
GB0224084D0 (en) * 2002-10-16 2002-11-27 Glaxo Group Ltd Novel compounds
AU2003298094A1 (en) 2002-10-22 2004-05-13 Glaxo Group Limited Medicinal arylethanolamine compounds
JP2006512404A (ja) * 2002-10-22 2006-04-13 グラクソ　グループ　リミテッド Ｈ３受容体リガンドとしてのアリールオキシアルキルアミン誘導体
DE60320007T2 (de) 2002-10-28 2009-06-18 Glaxo Group Ltd., Greenford Phenthanolamin-Derivate zur Behandlung von Atemwegserkrankungen
GB0225030D0 (en) 2002-10-28 2002-12-04 Glaxo Group Ltd Medicinal compounds
GB0225540D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
GB0225535D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
GB0308333D0 (en) * 2003-04-10 2003-05-14 Glaxo Group Ltd Novel compounds
TWI328009B (en) 2003-05-21 2010-08-01 Glaxo Group Ltd Quinoline derivatives as phosphodiesterase inhibitors
PE20060272A1 (es) 2004-05-24 2006-05-22 Glaxo Group Ltd (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
WO2006000398A1 (en) 2004-06-28 2006-01-05 Glaxo Group Limited 2,3-benzoxazin derivatives as non-steroidal glucocorticoid receptor modulators
WO2006000401A1 (en) 2004-06-28 2006-01-05 Glaxo Group Limited Substituted oxazines as glucocorticoid receptor modulators
GB0418045D0 (en) 2004-08-12 2004-09-15 Glaxo Group Ltd Compounds
US7465795B2 (en) 2005-12-20 2008-12-16 Astrazeneca Ab Compounds and uses thereof
CA2649029A1 (en) 2006-04-20 2007-11-01 Glaxo Group Limited 2-substituted 4-benzylphthalazinone derivatives as histamine h1 and h3 antagonists

Also Published As

Publication number Publication date
BRPI0620218A2 (pt) 2011-11-01
US7989629B2 (en) 2011-08-02
PT1963307E (pt) 2010-03-03
ATE449769T1 (de) 2009-12-15
JP4445570B2 (ja) 2010-04-07
CA2634391A1 (en) 2007-06-28
KR20080087102A (ko) 2008-09-30
EP1963307B1 (en) 2009-11-25
EA014354B1 (ru) 2010-10-29
PL1963307T3 (pl) 2010-05-31
JP2009235087A (ja) 2009-10-15
WO2007071691A1 (en) 2007-06-28
US20080312280A1 (en) 2008-12-18
PE20071068A1 (es) 2007-12-13
MA30373B1 (fr) 2009-05-04
EP2157087A1 (en) 2010-02-24
NO20082695L (no) 2008-09-16
AU2006328512A1 (en) 2007-06-28
EP1963307A1 (en) 2008-09-03
DE602006010737D1 (de) 2010-01-07
HK1120265A1 (en) 2009-03-27
JP2009520001A (ja) 2009-05-21
TW200730498A (en) 2007-08-16
AR058109A1 (es) 2008-01-23
DK1963307T3 (da) 2010-04-06
AU2006328512B2 (en) 2011-06-23
EA200801342A1 (ru) 2008-12-30
CY1110601T1 (el) 2015-04-29
IL191967A0 (en) 2008-12-29
ES2337187T3 (es) 2010-04-21
SI1963307T1 (sl) 2010-03-31

Similar Documents

Publication Publication Date Title
ECSP14004812A (es) Triazolopiridinas sustituidas
EA201100944A1 (ru) Производные изоксазола, предназначенные для применения в качестве регуляторов роста растений
ECSP11010754A (es) Derivados de triazol útiles para el tratamiento de enfermedades
CO6351780A2 (es) Nuevas benzamidas, su preparaccion y su uso como medicamentos
PE20141540A1 (es) Derivados de 2-amino-4-(piridin-2-il)-5,6-dihidro-4h-1,3-oxazina y su uso como inhibidores de bace-1 y/o bace-2
CY1116791T1 (el) 4-αρυλ-ν-φαινυλ-1,3,5-τριαζιν-αμινες που περιεχουν μια ομαδα σουλφοξιμινης
MX2009009492A (es) Compuestos organicos biciclicos adecuados para el tratamiento de condiciones inflamatorias o alergicas.
NI201500142A (es) Derivados de 3-acetilamino-1 (fenil-heteroaril-aminocarbonil o fenil-heteroaril-carbonilamino) benceno para el tratamiento de desordenes hiperproliferativos.
EA201200918A1 (ru) Производные пирролидин карбоновой кислоты как агонисты сопряженного с g-белком рецептора 43 (gpr43), фармацевтическая композиция и методы их использования при лечении метаболических нарушений
EA201070535A1 (ru) Новые агонисты глюкокортикоидных рецепторов
ECSP10010582A (es) Derivados de aminodihidrotiazina como inhibidores de bace para el tratamiento de la enfermedad de alzheimer
DOP2009000287A (es) Oxazolidinonas sustituidas y su uso
EA201100921A1 (ru) Соединения, фармацевтические композиции и способы их применения при лечении нарушений обмена веществ
CU20120171A7 (es) Triazolopiridinas sustituidas
NI201500134A (es) Derivados de 2-((4-amino-3-(3-flúor-5-hidroxifenil)-1h-pirazolo[3,4-d]pirimidin-1-il) metil)-3-(2-(trifluorometil)bencil)quinazolina-4(3h)-ona y su uso como inhibidores de fosfoinositida 3-quinasas
CY1110601T1 (el) 3-(4-{[4-(4-{[3-(3,3-διμεθυλ-1-πιπεριδινυλ)προπυλ[οξυ] φαινυλ)-1-πιπεριδινυλ] καρβoνυλ}-1-ναφθαλινυλ) προπανοϊκο ή προπενοϊκο οξυ ως ανταγωνιστες η1 και η3 υποδοχεα για την θεραπεια φλεγμονωδων ή/και αλλεργικων διαταραχων
FR2978643B1 (fr) Composition herbicide a efficacite amelioree, methode de preparation et utilisation
CY1115800T1 (el) Παραγωγα της 3-(ετεροαρυλο-αμινο)-1,2,3,4-τετραϋδρo-9η-καρβαζολης και η χρηση τους ως ρυθμιστες των υποδοχεων της προσταγλανδινης d2
PE20081700A1 (es) Derivados de acido de piranona sustituidos como agentes para tratar el sindrome metabolico
MX379859B (es) Compuestos de indolinona y su uso en el tratamiento de enfermedades fibróticas.
ECSP11011473A (es) Antagonistas de ccr3 de arilsulfonamida 2, 5- disustituída
MA32945B1 (fr) Tétrahydropyrane spiro pyrrolidinone et pipéridinone substituées, leur préparation et leur utilisation thérapeutique
AR085909A1 (es) Derivados de azaespirodecanona, composiciones farmaceuticas que los contienen, procedimiento para prepararlos y uso de los mismos para el tratamiento de diabetes, obesidad y enfermedades cardiovasculares, entre otras
ECSP099328A (es) Análogos de pirazol
MX2018002759A (es) Forma cristalina del inhibidor del receptor androgenico y metodo de preparacion de la misma.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)